Search Results | MSF Science Portal

Journal Article

|

Research

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, et al.

2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article

|

Short Report

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, et al.

2019-11-02 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Journal Article

|

Research

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, et al.

2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Journal Article

|

Commentary

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M, et al.

2020-10-01 • International Journal of Tuberculosis and Lung Disease

In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

Journal Article

|

Research

Mbuagbaw L, Guglielmetti L, Hewison CCH, Bakare N, Bastard M, et al.

2019-05-01 • Emerging Infectious Diseases

Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...

Journal Article

|

Research

Ardizzoni E, Mulders W, Kotrikadze T, Goginashvili L, Pangtey H, et al.

2015-12-02 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
Molecular techniques rapidly detect resistance to rifampicin (RMP) and isoniazid (INH), but do not eliminate the need for culture-based drug susceptibility testing (DST) a...

Journal Article

|

Research

Hewison CCH, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, et al.

2018-07-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.

OBJECTIVE
To assess the effectiveness and safety of multidrug...

Technical Report

|

Study report

Atwood S, Avagyan N, Bastard M, Cain M, Collin S, et al.

2018-07-01

Science Portal

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Introducing new and repurposed TB drugs: the endTB experience

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

The thin-layer agar method for direct phenotypic detection of multi- and extensively drug-resistant tuberculosis

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns